70 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
. David Young, Chief Executive Officer of Processa Pharmaceuticals. “The asset aligns with our mission to identify and bring to market better and safer … Pharmaceuticals, Inc.
The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
25 Feb 20
Processa Pharmaceuticals Provides Shareholder Update
9:30am
was a year of significant accomplishments for Processa, and we have no plans to slow down in 2020. Our mission is to develop drug products for patients … in Hanover, Maryland after the acquisition of Promet Therapeutics, LLC (formed in January 2016). The mission of Processa has been to develop products
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
26 Jan 22
Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022
8:15am
and its mission. We don’t believe value creation comes from bloated payrolls for executives in the C-suite; it comes from generating compelling … Pharm.D., Ph.D.
CEO, Processa Pharmaceuticals
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
11 Jan 21
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
1:35pm
be viewed on our website at https://processapharmaceuticals.com/investors-events.php.
About Processa Pharmaceuticals, Inc.
The mission of Processa
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
6 Dec 18
Processa Pharmaceuticals Announces Up-listing to Otcqb Market
9:00am
Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. was founded in 2017 in Hanover, Maryland, with a mission to develop products that can improve the survival
8-K
EX-99.1
5hh435c c8b
20 Dec 19
Processa Pharmaceuticals Announces 1 for 7 Reverse Stock Split of Its Common Stock
4:20pm
8-K
EX-99.2
fyolc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.1
0kj7wq6tec
13 Oct 20
Processa Pharmaceuticals Announces Appointment of Michael Floyd as Chief Operating Officer
9:30am
8-K
EX-99.1
42qyn5nvffb yqt
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
8-K
EX-99.1
ynohr6z3wr
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
8-K
EX-99.1
f689hd pn
13 Feb 20
Processa Pharmaceuticals Appoints
9:30am
8-K
EX-99.1
7xsld mb2u3
3 Oct 18
Processa Pharmaceuticals Receives Fda Clearance
12:00am
8-K
EX-99.1
53glp7ii5cq6i4dcca
9 Jan 19
Processa Pharmaceuticals Announces Presentation
9:00am
8-K
EX-99.1
ko8tme7 utks5w
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
8-K
EX-99.1
4a7vduxfg66 40ib
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-99.1
4s68gm3lrk5t3h
30 Mar 20
Processa Pharmaceuticals to Move Forward with a PCS499 Phase 3 Trial after a Successful Fda Meeting
4:00pm
8-K
EX-99.2
hofan0j3v p1oj
4 Sep 19
Entry into a Material Definitive Agreement
5:19pm
8-K
EX-99.1
cetzqh4y
4 Aug 22
Regulation FD Disclosure
9:30am
8-K
EX-99.1
0o85k 1xf5
1 Jun 18
Entry into a Material Definitive Agreement
8:26am
8-K
EX-99.1
mfn9g
5 Mar 20
Processa Pharmaceuticals Announces Formation of Its Medical and Scientific Advisory Board
9:30am